da-7867 profile

DA-7867: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10409343
CHEMBL ID	1760986
SCHEMBL ID	6793230
MeSH ID	M0458868

Synonym
da-7867
n-[[(5s)-3-[3-fluoro-4-[6-(1-methyltetrazol-5-yl)-3-pyridyl]phenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
CHEMBL1760986
380382-38-7
unii-491mt9gu8k
acetamide, n-(((5s)-3-(3-fluoro-4-(6-(1-methyl-1h-tetrazol-5-yl)-3-pyridinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-
491mt9gu8k ,
SCHEMBL6793230
(s)-n-(3-{3-fluoro-4-[6-(1-methyl-1h-tetrazol-5-yl)-pyridine-3-yl]-phenyl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide
n-[[(5s)-3-[3-fluoro-4-[6-(1-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
Q27259201
AKOS040745707

Research Excerpts

Pharmacokinetics

DA-7867, a new oxazolidinone, was compared after intravenous and oral administration at a dose of 10 mg x kg(-1) to control rats and rats with protein-calorie malnutrition.

Excerpt	Reference	Relevance
"The pharmacokinetic parameters of DA-7867, a new oxazolidinone, were compared after intravenous and oral administration at a dose of 10 mg x kg(-1) to control rats and rats with protein-calorie malnutrition (rats with PCM)."	( Effects of protein-calorie malnutrition on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. Bae, SK; Kim, WB; Kwon, JW; Lee, MG; Lee, SJ, 2004)	0.84
"The pharmacokinetic parameters of DA-7867 were compared after intravenous and oral administration at a dose of 10 mg/kg to control rats and rats with acute renal failure induced by uranyl nitrate (rats with U-ARF)."	( Effects of acute renal failure on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. Bae, SK; Kim, WB; Kwon, JW; Lee, I; Lee, MG, 2006)	0.86
"The pharmacokinetic parameters of DA-7867 were compared after intravenous and oral administration at a dose of 10 mg/kg in control rats and in rats with water deprivation for 72 h (rat model of dehydration)."	( Effects of water deprivation for 72 hours on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. Bae, SK; Kim, YC; Kwon, JW; Lee, I; Lee, JK; Lee, MG; Yoo, M, 2006)	0.85

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay ID	Title	Year	Journal	Article
AID590060	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by agar dilution method	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.
AID590061	Antibacterial activity against vancomycin-resistant Enterococcus by agar dilution method	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.
AID590059	Antibacterial activity against methicillin-resistant Staphylococcus aureus by agar dilution method	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.
AID590155	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (94.12)	29.6817
2010's	1 (5.88)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
proadifen Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.	2.02	1	diarylmethane
dimethylnitrosamine Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.	2.02	1	nitrosamine	geroprotector; mutagen
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.03	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	4.16	16	carbamate ester; oxazolidinone	metabolite
garenoxacin garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.	7.02	1	aromatic ether; cyclopropanes; isoindoles; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; non-steroidal anti-inflammatory drug
linezolid [no description available]	2.94	4	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
tedizolid DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	2.45	2	carbamate ester; organofluorine compound; oxazolidinone; primary alcohol; pyridines; tetrazoles	antimicrobial agent; drug metabolite; protein synthesis inhibitor

Condition	Relationship Strength	Studies
Cerebral Nocardiosis [description not available]	2.43	2
Actinomycetales Infections Infections with bacteria of the order ACTINOMYCETALES.	2.04	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.42	2
Bacterial Disease [description not available]	2.02	1
Bacterial Infections Infections by bacteria, general or unspecified.	2.02	1
Bacterial Skin Diseases [description not available]	2.02	1
Skin Diseases, Bacterial Skin diseases caused by bacteria.	2.02	1
Malnourishment [description not available]	2.02	1
Malnutrition An imbalanced nutritional status resulting from insufficient intake of nutrients to meet normal physiological requirement.	7.02	1
Cirrhoses, Experimental Liver [description not available]	2.02	1
Alloxan Diabetes [description not available]	2.02	1
Bacterial Infections, Gram-Positive [description not available]	2.02	1
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	2.02	1
Acute Kidney Failure [description not available]	2.03	1
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	2.03	1
Dehydration The condition that results from excessive loss of water from a living organism.	2.03	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.03	1
Weight Reduction [description not available]	2.03	1
Weight Loss Decrease in existing BODY WEIGHT.	2.03	1

da-7867

Description

Cross-References

Synonyms (12)

Research Excerpts

Pharmacokinetics

Bioassays (4)

Research

Studies (17)

Market Indicators

Research Demand Index: 11.35

Study Types

da-7867

Description

Cross-References

Synonyms (12)

Research Excerpts

Pharmacokinetics

Bioassays (4)

Research

Studies (17)

Market Indicators

Research Demand Index: 11.35

Study Types

Related Drugs (7)

Related Conditions (19)